Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Screening Visit~  * Age: 19-80~ * High risk for cardiovascular disease according to NCEP APT III~ * TG≥130mg/dL and 160mg/dL\>LDL-C≥100mg/dL for subjects who were not taking statins for 4 weeks~ * 500mg/dL\>TG≥200mg/dL and LDL-C\<110mg/dL for subjects who were taking statins for 4 weeks~* Baseline Visit~  * 500mg/dL\>TG≥200mg/dL~ * LDL-C\<110mg/dL~ * Reduction of LDL-C dompairng screening visit~Exclusion criteria:~* The patient has histories of acute artery disease within 3 months~* The patient has histories of operation revasculatiation or aneurysm within 6 months~* The patient has histories of Unexplained myaliga or diagnosed myalgia or rhabdomyolysis~* The patient has histories of Effectable disease to the procedrue and clinical trial result

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): KI1107
- Control (Type: ACTIVE_COMPARATOR): Rosuvastatin calcium

Based on this trial design, predict the completion outcome and termination type (if applicable).